Deal Library / Pharma BD Deal Intelligence

Boehringer Ingelheim — Pharma Deals

The Pharma Closeout tracks 13 deals, $607M in disclosed deal value, 1 with a post-close Outcome Score for Boehringer Ingelheim.

Median Critic Score: 50  ·  Median Outcome Score: 52

All 13 deals

• Boehringer Ingelheim / Boehringer Ingelheim Shionogi Vetmedica (Shionogi stake) — 2004 · Mixed — partial payoff, real shortfalls.
• Boehringer Ingelheim / Variant Bio — 2026
• Boehringer Ingelheim / Jazz Pharmaceuticals — 2026
• Boehringer Ingelheim / ViVerita Therapeutics — 2025
• Boehringer Ingelheim / Re-Vana Therapeutics — 2025
• Boehringer Ingelheim / Salipro Biotech AB — 2025
• Boehringer Ingelheim / Brainomix — 2024
• Boehringer Ingelheim / Mary Tyler Moore Vision Initiative — 2024
• Boehringer Ingelheim / 3T Biosciences — 2024
• Boehringer Ingelheim / Circle Pharma — 2024 · $607M
• Boehringer Ingelheim / Surrozen, Inc. — 2022
• Boehringer Ingelheim / Mirati Therapeutics, Inc. — 2020
• Boehringer Ingelheim / ViraTherapeutics — 2016

← Deal Library  ·  Interactive search  ·  How we score deals